Ideongatan 3 A-B
Lund 223 70
Sweden
46 4 62 75 67 77
https://www.iconovo.se
Sector(es): Healthcare
Sector: Medical Devices
Empleados a tiempo completo: 28
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Johan Waborg | Chief Executive Officer | N/A | N/A | 1977 |
Dr. Orest Lastow | Co-Founder, CTO, Innovation Lead & Director | N/A | N/A | 1964 |
Mr. Henrik Damkjaer Simonssen M.Sc. | Chief Financial Officer | N/A | N/A | 1963 |
Dr. Mikael Arinder | Vice President of Operations | N/A | N/A | 1964 |
Josefin Olsen | HR Manager | N/A | N/A | N/A |
Mr. Carl Forslund | Head of Industrial Design | N/A | N/A | N/A |
Therese Dahl | Business Controller | N/A | N/A | N/A |
Iconovo AB (publ) develops and licenses inhalation medications in Sweden. The company offers ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone Nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has collaboration agreement with the French biotechnology company Affilogic, ENA Respiratory Pty Ltd, and Stevanato Group, as well as licensing agreements with Kiox Pharma and Monash University. Iconovo AB (publ) was founded in 2013 and is headquartered in Lund, Sweden.
El ISS Governance QualityScore de Iconovo AB (publ), a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.